REG - Nuformix PLC - Result of AGM

NuformixAnnouncement

Today 10:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260303:nRSC1182Va&default-theme=true

RNS Number : 1182V  Nuformix PLC  03 March 2026

3 March 2026

Nuformix plc

("Nuformix" or the "Company")

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that
the Annual General Meeting of Nuformix plc was held earlier today and all
resolutions put to shareholders were duly passed and approved by a show of
hands.  The proxies received ahead of the AGM, are reported below:

     Resolution                                                                      Ordinary/ Special  For                   Against              Total votes cast  Withheld
                                                                                                        No. of votes  %       No. of votes  %
 1   To receive the annual report and accounts for the year ended 30 September 2025  Ordinary           214,955,860   99.92%  177,416       0.08%  215,133,276       8,248,030

 2   To approve the Annual Report on Remuneration                                    Ordinary           220,295,243   99.84%  357,453       0.16%  220,652,696       2,728,610

 3   To re-appoint Daniel Gooding as a director                                      Ordinary           220,637,188   99.85%  327,691       0.15%  220,964,879       2,416,427

 4   To re-appoint Julian Gilbert as a director                                      Ordinary           220,625,354   99.85%  339,525       0.15%  220,964,879       2,416,427

 5   To re-appoint Madeleine Kennedy as a director                                   Ordinary           217,650,945   99.84%  347,691       0.16%  217,998,636       5,382,670

 6   To re-appoint Kreston Reeves LLP as auditor                                     Ordinary           220,393,106   99.73%  605,530       0.27%  220,998,636       2,382,670

 7   To authorise the Directors to determine the auditor's fees.                     Ordinary           219,520,242   99.37%  1,398,865     0.63%  220,919,107       2,462,199

 8   To authorise the Directors to allot shares.                                     Ordinary           209,386,402   97.46%  5,449,425     2.54%  214,835,827       8,545,479

 9   To authorise the Directors to disapply pre-emption rights.                      Special            211,574,241   98.46%  3,311,586     1.54%  214,885,827       8,495,479

 10  To authorise the Company to purchase its own shares.                            Special            213,681,044   95.98%  8,956,820     4.02%  222,637,864       743,442

 11  To authorise calling of a general meeting on 14 clear days' notice.             Special            222,647,463   99.88%  277,416       0.12%  222,924,879       456,427

 

 

A vote withheld is not a vote in law and is not counted in the calculation of
votes validly cast for or against a resolution.

The Company's issued share capital is 2,109,749,903 ordinary shares of
£0.0005 each.

Enquiries:

 Nuformix plc
 Dr Dan Gooding, Executive Director  Via IFC Advisory

 CMC Markets
 Douglas Crippen                     +44 (0) 20 3003 8632

 IFC Advisory Limited
 Tim Metcalfe                        +44 (0) 20 3934 6632

 Zach Cohen                          nuformix@investor-focus.co.uk

 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities.  Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com
(http://www.nuformix.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGKXLBBQXLXBBV



            Copyright 2019 Regulatory News Service, all rights reserved